Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric ...

Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.

The FDA previously rejected Zycubo for Menkes disease in October last year, citing issues with the drug’s manufacturing ...

Investing.com -- The U.S. Food and Drug Administration (FDA) approved Zycubo (copper histidinate) injection on Monday as the ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for ...

ZYCUBO is a subcutaneous injectable formulation of copper histidinate designed to restore copper homeostasis and maintain adequate copper levels in patients with Menkes disease.

The California department of health recommended that people avoid mushroom foraging, warning that death cap mushrooms have ...

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, ...

The FDA approved copper histidinate (Zycubo) as the first treatment for Menkes disease in pediatric patients, the agency ...

Biogen Inc. ( BIIB) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST ...

The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for ...